Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 476-480

  Bruxel, E M ^a   Salatino Oliveira, A ^a   Genro, J P ^a   Zeni, C P ^b   Polanczyk, G V ^b   Chazan, R ^b   Rohde, L A ^b,c   Hutz, M H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Instituto de Psiquiatria Do Desenvolvimento Para A Infância e Adolescência   (Brazil)

Author keywords

adverse reaction; appetite reduction; attention deficit hyperactivity disorder; carboxylesterase 1; methylphenidate; pharmacogenetics

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; DNA; GUANINE; METHYLPHENIDATE; THYMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; BARKLEY STIMULANT SIDE EFFECT RATING SCALE; CHILD; DECREASED APPETITE; DNA EXTRACTION; DRUG DOSE INCREASE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ALLELES; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARBOXYLIC ESTER HYDROLASES; CHILD; FEMALE; HOMOZYGOTE; HUMANS; MALE; METHYLPHENIDATE; POLYMORPHISM, GENETIC;

EID: 84884589710     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.25     Document Type: Article

References (41)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007a; 164: 942-948.
2. Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004; 65: 22-26.
3. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30: 17-26.
4. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6: 6.
5. Szobot CM, Roman T, Hutz MH, Genro JP, Shih MC, Hoexter MQ et al. Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity. Synapse 2011; 65: 154-159.
6. Kieling C, Genro JP, Hutz MH, Rohde LA. A current update on ADHD pharmacogenomics. Pharmacogenomics 2010; 11: 407-419.
7. Polanczyk G, Bigarella MP, Hutz MH, Rohde LA. Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des 2010; 16: 2462-2473.
8. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1314-1322.
9. McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR et al. A candidate gene analysis of methylphenidate response in attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1155-1164.
10. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23: 1281-1299.
11. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008; 82: 1241-1248.
12. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009; 57: 731-733.
13. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazidinduced hepatotoxicity. Pharmacogenomics J 2010; 10: 524-536.
14. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004; 13: 17-30.
15. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 1996; 98: 763-769.
16. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894-921.
17. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22: 213-237.
18. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662-666.
19. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1294-1303.
20. Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil 2006; 27: 162-174.
21. Zeni CP, Guimarães AP, Polanczyk GV, Genro JP, Roman T, Hutz MH et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 391-394.
22. Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2007b; 64: 218-224.
23. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. Guilford Press: New York, 1990.
24. Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 2004; 14: 195-206.
25. Rohde LA. ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131-1133.
26. Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
27. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739-750.
28. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9-21.
29. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeatedmeasures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310-317.
30. Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 1129-1139.e1122.
31. Cohen J, Cohen P, West SG, Aiken LS. Applied Multiple Regression/Correlation Analysis for the Behavioral Science. Mahwah: Erlbaum, NJ, 2003.
32. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-1323.
33. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL et al. A doseresponse study of OROS methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2003; 112: e404.
34. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180-187.
35. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184-192.
36. Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS et al. Influence of methylphenidate on eating in obese men. Obes Res 2004; 12: 224-232.
37. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009; 19: 493-499.
38. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009; 19: 683-690.
39. Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry 2011; 11: 70.
40. Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 2007; 32: 2199-2206.
41. Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P et al. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J Child Adolesc Psychopharmacol 2009; 19: 127-136.